Annovis Bio Shares Soar on New Phase 3 Data in Parkinson’s Disease
    Annovis Bio Shares Soar on New Phase 3 Data in Parkinson’s Disease
    PRISM Biotech

    July 08, 2024 - by Catie Corcoran

    Annovis Bio Shares Soar on New Phase 3 Data in Parkinson’s Disease

    08 July 2024

    New York, July 8, 2024 - PRISM MarketView - Shares in late-stage clinical drug platform company Annovis Bio (Nasdaq: ANVS) soared nearly 40% on Friday after the company announced new data from its Phase 3 Parkinson’s disease study. The study has demonstrated that buntanetap is safe and effective in improving motor and non-motor activities and improving cognitive functions in patients with early Parkinson’s disease. The company topped the PRISM Emerging Global Health Index at the end of the week.
    Annovis Bio, Inc. - Prism MarketView

    Annovis Bio, Inc. - Prism MarketView

    Annovis Bio, Inc.’s novel approach to addressing chronic and acute neurodegeneration offers new hope in the fight against the largest unmet need of an aging p

    Read More

    Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap

    Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap

    Changes in MMSE after treatment with 10mg or 20mg buntanetap compared to baseline and placebo Figure 1. Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with a PD diagnosis over 3 years compared to baseline and placebo Figure 2. Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with PIGD Figure 3. Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s pati

    Read More

    Patients in the study’s placebo group demonstrated cognition deterioration for the duration of the trial, while buntanetap maintained baseline levels, indicating a statistically significant effect of the drug in stopping cognitive decline. Buntanetap was also found to improve functions in patients with Postural Instability and Gait Difficulty (PIGD).

    “We are very pleased to see improvements in many of our patients over such a short course of treatment. These compelling data reinforce our commitment to advancing buntanetap into a longer study, which will allow us not only to verify observed symptomatic improvements but also to explore buntanetap’s disease-modifying properties.”

    Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis Bio

    Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins and aims to reverse neurodegeneration, restore brain function and improve quality of life for patients living with Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases.
    About Annovis Bio, Inc.
    Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

    To see this content properly accept cookies.
    To see this content properly accept cookies.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.